このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Pfizer 過去の業績

過去基準チェック /16

Pfizerは、平均年間4.5%の収益成長を遂げていますが、 Pharmaceuticals業界の収益は、年間成長しています。収益は、平均年間17% 2.3%収益成長率で成長しています。 Pfizerの自己資本利益率は15.3%であり、純利益率は25.1%です。

主要情報

4.5%

収益成長率

4.5%

EPS成長率

Pharmaceuticals 業界の成長	17.5%
収益成長率	2.3%
株主資本利益率	15.3%
ネット・マージン	25.1%
前回の決算情報	31 Mar 2024

Weak Statutory Earnings May Not Tell The Whole Story For Pfizer (NSE:PFIZER)

May 25

Recent updates

This Is The Reason Why We Think Pfizer Limited's (NSE:PFIZER) CEO Deserves A Bump Up To Their Compensation

Aug 12

Are Institutions Heavily Invested In Pfizer Limited's (NSE:PFIZER) Shares?

Mar 10

Why Dividend Hunters Love Pfizer Limited (NSE:PFIZER)

Feb 17

Are Pfizer's (NSE:PFIZER) Statutory Earnings A Good Guide To Its Underlying Profitability?

Feb 02

Need To Know: Pfizer Limited (NSE:PFIZER) Insiders Have Been Buying Shares

Jan 18

Is Pfizer Limited's (NSE:PFIZER) Stock's Recent Performance A Reflection Of Its Financial Health?

Jan 03

What Can We Learn About Pfizer's (NSE:PFIZER) CEO Compensation?

Dec 18

Here's What Pfizer Limited's (NSE:PFIZER) Shareholder Ownership Structure Looks Like

Dec 03

Did You Participate In Any Of Pfizer's (NSE:PFIZER) Fantastic 174% Return ?

Nov 18

Are Pfizer's (NSE:PFIZER) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Nov 03

Need To Know: Pfizer Limited (NSE:PFIZER) Insiders Have Been Buying Shares

Oct 20

Pfizer Limited's (NSE:PFIZER) Stock Is Going Strong: Is the Market Following Fundamentals?

Oct 02

Why Pfizer's (NSE:PFIZER) CEO Pay Matters

Sep 17

収支内訳

Pfizer の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NSEI:PFIZER 収益、費用、利益 ( )INR Millions
日付	収益	収益	G+A経費	研究開発費
31 Mar 24	21,932	5,513	3,478	0
31 Dec 23	22,192	5,021	3,998	0
30 Sep 23	23,010	5,228	4,021	0
30 Jun 23	23,632	6,849	3,948	0
31 Mar 23	24,248	6,239	3,935	0
31 Dec 22	24,041	6,201	4,334	0
30 Sep 22	24,583	6,133	4,514	0
30 Jun 22	24,571	4,452	4,762	0
31 Mar 22	26,110	6,126	4,784	0
31 Dec 21	25,961	5,873	4,720	0
30 Sep 21	25,137	5,847	4,564	0
30 Jun 21	24,728	5,731	4,353	0
31 Mar 21	22,404	4,976	4,266	0
31 Dec 20	22,058	5,001	4,555	0
30 Sep 20	21,505	4,979	4,514	0
30 Jun 20	21,221	5,208	3,628	0
31 Mar 20	21,517	5,091	4,531	0
31 Dec 19	21,853	5,156	4,628	0
30 Sep 19	21,609	5,085	4,565	0
30 Jun 19	21,136	4,500	4,483	0
31 Mar 19	20,815	4,291	4,416	0
31 Dec 18	20,658	4,241	4,377	0
30 Sep 18	20,085	3,794	4,196	0
30 Jun 18	20,599	3,947	3,142	0
31 Mar 18	19,685	3,601	4,210	0
31 Dec 17	18,866	3,236	3,911	0
30 Sep 17	19,215	2,987	4,130	0
30 Jun 17	18,860	3,139	3,090	0
31 Mar 17	19,663	3,368	4,086	0
31 Dec 16	20,453	2,737	4,452	0
30 Sep 16	20,595	2,711	4,357	0
30 Jun 16	20,350	2,276	4,237	0
31 Mar 16	20,123	3,050	4,068	0
31 Dec 15	19,649	1,680	5,755	0
30 Sep 15	19,334	1,460	5,603	0
30 Jun 15	19,018	861	5,583	0
31 Mar 15	18,531	698	3,594	0
31 Dec 14	16,632	1,137	4,199	9
30 Sep 14	11,078	1,380	3,817	9
30 Jun 14	11,118	2,194	1,722	0
31 Mar 14	11,103	2,209	3,936	0
31 Dec 13	11,161	2,230	4,163	79
30 Sep 13	11,002	2,393	4,281	79

質の高い収益: PFIZER 非現金収入のレベルが高いです。

利益率の向上: PFIZERの現在の純利益率 (25.1%)は、昨年(25.7%)よりも低くなっています。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: PFIZERの収益は過去 5 年間で年間4.5%増加しました。

成長の加速: PFIZERは過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。

収益対業界: PFIZERは過去 1 年間で収益成長率がマイナス ( -11.6% ) となったため、 Pharmaceuticals業界平均 ( 18% ) と比較することが困難です。

株主資本利益率

高いROE: PFIZERの自己資本利益率 ( 15.3% ) は低いとみなされます。

Pfizer 過去の業績

過去 基準チェック /16

主要情報

最近の業績更新

Weak Statutory Earnings May Not Tell The Whole Story For Pfizer (NSE:PFIZER)

Full year 2024 earnings released: EPS: ₹121 (vs ₹136 in FY 2023)

Pfizer Limited to Report Q4, 2024 Results on May 17, 2024

Third quarter 2024 earnings released: EPS: ₹28.42 (vs ₹32.93 in 3Q 2023)

Pfizer Limited to Report Q3, 2024 Results on Feb 09, 2024

Second quarter 2024 earnings released: EPS: ₹32.56 (vs ₹67.99 in 2Q 2023)

Recent updates

Weak Statutory Earnings May Not Tell The Whole Story For Pfizer (NSE:PFIZER)

Full year 2024 earnings released: EPS: ₹121 (vs ₹136 in FY 2023)

Pfizer Limited Recommends Dividend for the Financial Year Ended March 31, 2024, Payable on or Before September 6, 2024

Pfizer Limited to Report Q4, 2024 Results on May 17, 2024

Pfizer Limited Appoints Amit Agarwal as Chief Financial Officer

China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for Enfortumab Vedotin with Keytruda (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

Pfizer (NSE:PFIZER) Has A Pretty Healthy Balance Sheet

Third quarter 2024 earnings released: EPS: ₹28.42 (vs ₹32.93 in 3Q 2023)

Pfizer Limited Informs Satyen Amin, Lead - Market Access Tenders His Resignation from Employment, with Effect from March 31, 2024

Pfizer Limited to Report Q3, 2024 Results on Feb 09, 2024

Pfizer Limited's (NSE:PFIZER) Business Is Yet to Catch Up With Its Share Price

Pfizer Limited Appoints Ms. Aditi Mehta as Category Lead, Vaccines Effective December 1, 2023

Pfizer Limited Announces Resignation of Mr. Milind Patil as Director with Effect from Close of Business on November 13, 2023

Pfizer Limited Announces Resignation of Samir Kazi as Director from the Board of Directors

Second quarter 2024 earnings released: EPS: ₹32.56 (vs ₹67.99 in 2Q 2023)

Pfizer Limited to Report Q2, 2024 Results on Oct 28, 2023

Pfizer Limited Appoints Chaitanya Nadkarni as India Digital Client Partner Lead

Pfizer Limited Approves A Final Dividend for the Financial Year Ended March 31, 2023

New major risk - Revenue and earnings growth

Pfizer Limited Announces Change in Management, Effective September 1, 2023

Pfizer Limited to Report Q1, 2024 Results on Aug 11, 2023

Upcoming dividend of ₹40.00 per share at 0.9% yield

Full year 2023 earnings released: EPS: ₹136 (vs ₹134 in FY 2022)

Pfizer Limited, Annual General Meeting, Aug 18, 2023

Pfizer Limited Proposes Final Dividend for the Financial Year Ended March 31, 2023

Pfizer Limited Initiates Voluntary Recall Of Magnex 1gm, 2gm, Magnex Forte 1.5gm, 3gm, Zosyn 4.5gm and Magnamycin 250mg, 1gm, 2gm Injections

Price target decreased by 7.9% to ₹4,595

Pfizer Limited Recommends A Final Dividend for the Financial Year Ended March 31, 2023, Payable on or Before September 16, 2023

Full year 2023 earnings released: EPS: ₹136 (vs ₹134 in FY 2022)

Pfizer Limited to Report Fiscal Year 2023 Results on May 15, 2023

Here's Why Pfizer (NSE:PFIZER) Can Manage Its Debt Responsibly

Third quarter 2023 earnings released: EPS: ₹32.93 (vs ₹31.46 in 3Q 2022)

Pfizer India Appoints Meenakshi Nevatia as CEO

Second quarter 2023 earnings released: EPS: ₹67.99 (vs ₹31.25 in 2Q 2022)

Insufficient new directors

Second quarter 2023 earnings released: EPS: ₹67.99 (vs ₹31.25 in 2Q 2022)

Upcoming dividend of ₹30.00 per share

Pfizer Limited Announces Interim (Special) Dividend for the Financial Year Ending March 31, 2023, Payable on or Before September 30, 2022

Pfizer Limited Approves Declaration of Dividend for the Financial Year Ended March 31, 2022

Upcoming dividend of ₹35.00 per share

Pfizer Announces Resignation of S. Sridhar as Managing Director

Pfizer Limited Proposes Dividend for the Financial Year Ended March 31, 2022

First quarter 2023 earnings released

Pfizer Limited Proposes Dividend for the Financial Year Ended March 31, 2022

Mylan Pharmaceuticals Private Limited completed the acquisition of off-patent branded and generic established medicines business from Pfizer Limited (BSE:500680).

Pfizer Limited to Report Q1, 2023 Results on Aug 05, 2022

A Look At The Intrinsic Value Of Pfizer Limited (NSE:PFIZER)

Now 20% undervalued after recent price drop

Price target decreased to ₹5,201

Now 21% undervalued after recent price drop

Full year 2022 earnings released: EPS: ₹134 (vs ₹109 in FY 2021)

Pfizer Limited Recommends Dividend for the Financial Year Ended March 31, 2022, Payable on or before September 23, 2022

Price target decreased to ₹5,654

Insufficient new directors

Insufficient new directors

Pfizer (NSE:PFIZER) Could Easily Take On More Debt

Pfizer and FDA Dropped Data Bombshell on Covid Vaccine Consumers

Price target decreased to ₹5,749

Calculating The Fair Value Of Pfizer Limited (NSE:PFIZER)

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Pfizer Limited Announces Board Changes

Pfizer Limited Announces Resignation of R. A. Shah as an Independent Director

Second quarter 2022 earnings released: EPS ₹31.25 (vs ₹28.71 in 2Q 2021)

These 4 Measures Indicate That Pfizer (NSE:PFIZER) Is Using Debt Safely

This Is The Reason Why We Think Pfizer Limited's (NSE:PFIZER) CEO Deserves A Bump Up To Their Compensation

Upcoming dividend of ₹35.00 per share

Price target increased to ₹6,099

Price target increased to ₹5,945

First quarter 2022 earnings released: EPS ₹43.69 (vs ₹27.20 in 1Q 2021)

過去基準チェック /16